Top ▲
Gene and Protein Information  |
||||||
| class A G protein-coupled receptor, absent in rats and mice | ||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 7 | 359 | Xp22.33 and Yp11.3 | P2RY8 | P2Y receptor family member 8 | |
| Previous and Unofficial Names |
| G-protein coupled purinergic receptor P2Y8 | P2Y purinoceptor 8 | purinergic receptor P2Y8 |
| Database Links |
|
| Specialist databases | |
| GPCRdb | p2ry8_human (Hs) |
| Other databases | |
| Alphafold | Q86VZ1 (Hs) |
| ChEMBL Target | CHEMBL4523886 (Hs) |
| Ensembl Gene | ENSG00000182162 (Hs) |
| Entrez Gene | 286530 (Hs) |
| Human Protein Atlas | ENSG00000182162 (Hs) |
| KEGG Gene | hsa:286530 (Hs) |
| OMIM | 300525 (Hs) |
| Pharos | Q86VZ1 (Hs) |
| RefSeq Nucleotide | NM_178129 (Hs) |
| RefSeq Protein | NP_835230 (Hs) |
| UniProtKB | Q86VZ1 (Hs) |
| Wikipedia | P2RY8 (Hs) |
| Tissue Distribution
|
||||||||
|
||||||||
|
||||||||
|
||||||||
| Tissue Distribution Comments | ||||||||
| P2RY8 mRNA is expressed transciently in the neural plate and tailbud during Xenopus development [2]. | ||||||||
| Functional Assays
|
||||||||||
|
| Gene Expression and Pathophysiology Comments | |
| P2RY8 is reported to have oncogenic potential [6,9]. P2RY8-CRLF2 gene fusion, which results from PAR1 deletion of Xp22.3 and Yp11.3, is found to be associated with B-progenitor acute lymphoblastic leukemia (ALL) and ALL associated with Down syndrome [4,7-8,11]. Acute lymphoblastic leukemias in children with Down syndrome is associated with recurrent deletion of P2RY8 gene, which causes CRLR2 gene deregulation [5,10]. Somatic mutations in P2RY8 gene are identified in patients with diffuse large B-cell lymphoma (DLBCL) [9]. Increased expression of P2RY8 is found to be associated with leukemia [6]. A promoter swapping event juxtaposing SOX5 coding region to the P2RY8 promoter, which lead to the formation of a novel fusion gene involving P2RY8 and SOX5, is found to be associated with primary splenic follicular lymphoma (PSFL)[12] (Based on a single PSFL case). |
1. Adrian K, Bernhard MK, Breitinger HG, Ogilvie A. (2000) Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells. Biochim Biophys Acta, 1492 (1): 127-38. [PMID:11004484]
2. Bogdanov YD, Dale L, King BF, Whittock N, Burnstock G. (1997) Early expression of a novel nucleotide receptor in the neural plate of Xenopus embryos. J Biol Chem, 272 (19): 12583-90. [PMID:9139711]
3. Cantagrel V, Lossi AM, Boulanger S, Depetris D, Mattei MG, Gecz J, Schwartz CE, Van Maldergem L, Villard L. (2004) Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet, 41 (10): 736-42. [PMID:15466006]
4. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, Camitta BM, Carroll AJ, Devidas M et al.. (2012) Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 119 (15): 3512-22. [PMID:22368272]
5. Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, Jones L, Kinsey SE, Vora AJ, Mitchell CD et al.. (2011) Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood, 117 (7): 2129-36. [PMID:21106984]
6. Fujiwara S, Yamashita Y, Choi YL, Watanabe H, Kurashina K, Soda M, Enomoto M, Hatanaka H, Takada S, Ozawa K, Mano H. (2007) Transforming activity of purinergic receptor P2Y, G protein coupled, 8 revealed by retroviral expression screening. Leuk Lymphoma, 48 (5): 978-86. [PMID:17487742]
7. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, Carroll WL, Devidas M, Bowman WP, Camitta BM, Reaman GH, Hunger SP, Downing JR, Willman CL. (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 115 (26): 5312-21. [PMID:20139093]
8. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 115 (5): 1006-17. [PMID:19965641]
9. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL et al.. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA, 109 (10): 3879-84. [PMID:22343534]
10. Lundin C, Hjorth L, Behrendtz M, Nordgren A, Palmqvist L, Andersen MK, Biloglav A, Forestier E, Paulsson K, Johansson B. (2012) High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome. Genes Chromosomes Cancer, 51 (2): 196-206. [PMID:22072402]
11. Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR. (2009) Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet, 41 (11): 1243-6. [PMID:19838194]
12. Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC, Impera L, Lonoce A, Funes S, Macrì E, Iuzzolino P, Panagopoulos I, Specchia G, Rocchi M. (2007) Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma. Leukemia, 21 (10): 2221-5. [PMID:17554380]
